Home » Stocks » CORV

Correvio Pharma Corp. (CORV)

May 26, 2020 - CORV was delisted after being acquired by CXRXF
Stock Price: $0.420 USD 0.000 (0.00%)
Updated Jun 5, 2020 4:00 PM EDT
Market Cap 27.79M
Revenue (ttm) 32.63M
Net Income (ttm) -35.18M
Shares Out 66.19M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Jun 5, 2020
Last Price $0.420
Previous Close $0.420
Change ($) 0.000
Change (%) 0.00%
Day's Open -
Day's Range 0.416 - 0.420
Day's Volume 0
52-Week Range 0.210 - 2.790

News

Hide News
PRNewsWire - 7 months ago

NASDAQ: CORV TSX: CORV VANCOUVER, May 21, 2020 /PRNewswire/ - Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on comm...

PRNewsWire - 8 months ago

Securityholders Approve ADVANZ PHARMA Acquisition NASDAQ: CORV TSX: CORV VANCOUVER, May 15, 2020 /PRNewswire/ - Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), ...

Zacks Investment Research - 8 months ago

Correvio (CORV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 9 months ago

Correvio (CORV) delivered earnings and revenue surprises of 23.08% and -1.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Correvio (CORV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Benzinga - 1 year ago

Shares of Canadian specialty pharma Correvio Pharma Corp (NASDAQ: CORV) are retreating in reaction to an adverse FDA verdict.

Market Watch - 1 year ago

Shares of microcap Correvio Pharma Corp. CORV, +14.57% slid about 12% in premarket trade Tuesday, after the company said it has received a Complete Response Letter from the U.S.

24/7 Wall Street - 1 year ago

Correvio Pharma Corp. (NASDAQ: CORV) shares were crushed after the firm announced the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) decision...

Market Watch - 1 year ago

Shares of Correvio Pharma CORV, +7.69% tumbled 54% in premarket trading after the specialty drugmaker said it was considering a sale of the company or its assets.

Benzinga - 1 year ago

Correvio Pharma Corp CORV shares came under selling pressure Friday after a briefing document released ahead of the company's planned Adcom meeting showed that FDA staffers were not convin...

Market Watch - 1 year ago

Shares of Correvio Pharma Corp. were halted in advance of a Food and Drug Administration advisory committee meeting for its experimental atrial fibrillation therapy.

Seeking Alpha - 1 year ago

Correvio Pharma's (CORV) CEO Mark Corrigan on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Correvio Pharma Corp. (CORV) CEO Mark Corrigan on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Correvio Pharma Corp. (CORV) CEO Mark Corrigan on Q1 2019 Results - Earnings Call Transcript

About CORV

Correvio Pharma, a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its products comprise Aggrastat (tirofiban hydrochloride), (an intravenous anti-platelet drug for patients with acute coronary syndrome; and Brinavess (vernakalant IV), a novel, atrial-preferential antiarrhythmic agent for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute ... [Read more...]

Industry
Drug Manufacturers—Specialty & Generic
Founded
2018
Stock Exchange
NASDAQ
Ticker Symbol
CORV
Full Company Profile

Financial Performance

In 2019, CORV's revenue was $32.63 million, an increase of 13.81% compared to the previous year's $28.67 million. Losses were -$35.18 million, 112.2% more than in 2018.

Financial Statements